MARKET

VYNE

VYNE

VYNE Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.490
-0.020
-1.32%
After Hours: 1.490 0 0.00% 17:54 09/24 EDT
OPEN
1.520
PREV CLOSE
1.510
HIGH
1.530
LOW
1.490
VOLUME
418.70K
TURNOVER
--
52 WEEK HIGH
13.20
52 WEEK LOW
1.370
MARKET CAP
76.75M
P/E (TTM)
-0.7658
1D
5D
1M
3M
1Y
5Y
VYNE Therapeutics to Present at the Cantor Fitzgerald Investment Conference
BRIDGEWATER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the Cantor Fitzgerald Virtual Global Healthcare Conference,...
GlobeNewswire · 4d ago
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most lik...
Benzinga · 09/13 14:27
VYNE Therapeutics to Present at the H.C. Wainwright Annual Investment Conference
VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that David Domzalski, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually from September 13 - 15.
GlobeNewswire · 09/08 12:00
Vyne Therapeutics Granted U.S. Patent Titled 'Wax foamable vehicle and pharmaceutical compositions thereof'
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=6690&f=G&l=50&d=PTXT&p=134&S1=20210831&OS=20210831&RS=20210831
Benzinga · 08/31 13:58
Insider Trends: Selling By Insiders Lingers at VYNE Therapeutics
MT Newswires · 08/18 19:22
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
Insider Trends: Insider Sales Add to 90-Day Trend at VYNE Therapeutics
MT Newswires · 08/17 16:58
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VYNE. Analyze the recent business situations of VYNE Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VYNE stock price target is 5.00 with a high estimate of 10.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 133
Institutional Holdings: 23.88M
% Owned: 46.36%
Shares Outstanding: 51.51M
TypeInstitutionsShares
Increased
16
1.22M
New
16
2.01M
Decreased
23
6.33M
Sold Out
34
1.20M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
President/Chief Executive Officer/Director
David Domzalski
Chief Financial Officer/Treasurer
Tyler Zeronda
Chief Technology Officer
Garrett Galley
Chief Scientific Officer
Iain Stuart
General Counsel/Secretary
Mutya Harsch
Other
Matthew Wiley
Lead Director/Independent Director
Patrick Lepore
Director
Steven Basta
Independent Director
Sharon Barbari
Independent Director
Rex Bright
Independent Director
Anthony Bruno
Independent Director
Elisabeth Sandoval
No Data
About VYNE
Menlo Therapeutics Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions, such as atopic dermatitis, psoriasis and prurigo nodularis. The Company is focused on developing and commercializing a variety of solutions using its Molecule Stabilizing Technology (MST). The Company has a commercial-stage product, AMZEEQ, and several late-stage product candidates. It is also evaluating the use of serlopitant for the treatment of refractory chronic cough. The Company’s serlopitant is a small molecule, highly selective NK1-R antagonist. It is developing serlopitant as an once-daily oral tablet therapy.

Webull offers kinds of Menlo Therapeutics Inc stock information, including NASDAQ:VYNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VYNE stock methods without spending real money on the virtual paper trading platform.